Nanologica AB (publ)

STO-NICA
Nasdaq Stockholm
Healthcare Biotechnology
Global Rank
#39073
Country Rank
#561
Market Cap
16.29 M
Price
0.0477
Change (%)
3.76%
Volume
104,448

Nanologica AB (publ)'s latest marketcap:

16.29 M

As of 07/17/2026, Nanologica AB (publ)'s market capitalization has reached $16.29 M. According to our data, Nanologica AB (publ) is the 39073th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 16.29 M
Revenue (ttm) 3.29 M
Net Income (ttm) 2.49 M
Shares Out 328.77 M
EPS (ttm) 0.03
Forward PE 9.58
Ex-Dividend Date n/a
Earnings Date 08/27/2026
Market Cap Chart
Data Updated: 07/17/2026

Nanologica AB (publ)'s yearly market capitalization.

Nanologica AB (publ) has seen its market value grow from kr73.54 M to kr157.48 M since 2015, representing a total increase of 114.13% and an annual compound growth rate (CAGR) of 7.37%.
Date Market Cap(kr) Market Cap(USD) Change (%) Global Rank
07/17/2026 kr157.48 M $16.29 M 185.23% 39073
12/30/2025 kr68.93 M $7.29 M -57.14% 37885
12/30/2024 kr160.81 M $14.46 M -57.22% 36134
12/29/2023 kr375.92 M $37.07 M 33.47% 29817
12/30/2022 kr281.66 M $26.87 M -27.01% 30948
12/30/2021 kr385.87 M $42.45 M 3.67% 28541
12/30/2020 kr372.21 M $0 113.3% 25319
12/30/2019 kr174.5 M $18.55 M 230.19% 26681
12/28/2018 kr52.85 M $5.94 M 27.88% 29309
12/29/2017 kr41.33 M $5.03 M -43.81% 29101

Company Profile

About Nanologica AB (publ)

Nanologica AB (publ) is a nanotechnology company specializing in the development, manufacturing, and sale of nanoporous silica particles for life science applications worldwide.

Business Segments

  • Drug Development – Focused on innovative solutions for life science applications.
  • Chromatography – Offers advanced silica-based products for substance analysis and purification.

Key Products

  • NLAB Saga – A next-generation silica for preparative chromatography.
  • SVEA HPLC Analytical Columns – Designed for high-performance liquid chromatography.

Applications

The company's products are primarily used in the analysis and purification of substances, with a strong focus on peptides and diabetes drugs.

Innovation & Development

Nanologica is actively developing Nanoporous Amorphous Particles (NAP), a platform technology for inhalation therapies aimed at improving treatments for severe lung diseases.

Company Background

Founded in 2004, Nanologica AB (publ) is headquartered in Södertälje, Sweden.

Frequently Asked Questions

  • What is Nanologica AB (publ)'s (STO-NICA) current market cap?
    As of 07/17/2026, Nanologica AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $16.29 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Nanologica AB (publ) global market capitalization ranking is approximately 39073 as of 07/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.